Edition:
India

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

27.40USD
22 Nov 2017
Change (% chg)

$0.17 (+0.62%)
Prev Close
$27.23
Open
$27.23
Day's High
$27.54
Day's Low
$27.10
Volume
82,886
Avg. Vol
188,889
52-wk High
$28.90
52-wk Low
$11.30

Latest Key Developments (Source: Significant Developments)

Arena Pharmaceuticals reports Q3 loss per share $0.86
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Arena Pharmaceuticals Inc ::Arena Pharmaceuticals provides corporate update and reports third quarter 2017 financial results.Q3 loss per share $0.86.Q3 revenue $7.9 million.Q3 revenue view $5.5 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.67 -- Thomson Reuters I/B/E/S.Arena Pharmaceuticals Inc - ‍expect to complete full enrollment for etrasimod phase 2 study in ulcerative colitis this week​.Arena Pharmaceuticals Inc - ‍initiated etrasimod phase 2 study in primary biliary cholangitis​.  Full Article

Arena Pharmaceuticals, Eisai receive 'paragraph IV certification'
Thursday, 25 Aug 2016 

Arena Pharmaceuticals Inc : Co and Eisai Inc have received a 'paragraph IV certification' notification with respect to patents for Belviq . Notification is currently under investigation . Co and Eisai have 45 days from receipt of notification to file a patent infringement suit against ANDA filer .Patent infringement suit would result in stay of FDA approval of ANDA under statutory guidelines.  Full Article

Arena Pharmaceuticals reports Q2 loss per share $0.11
Tuesday, 9 Aug 2016 

Arena Pharmaceuticals Inc : Arena Pharmaceuticals reports second quarter 2016 financial results and provides corporate update . Q2 revenue $9.5 million versus I/B/E/S view $10.4 million . Q2 loss per share $0.11 .Q2 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

Arena Pharma, EISAI announce FDA approval of BELVIQ XR extended-release tablets
Tuesday, 19 Jul 2016 

Arena Pharmaceuticals Inc : BELVIQ XR is expected to be available in fall of 2016. . Arena pharmaceuticals inc says in connection with approval, arena will receive a $10 million milestone payment. . EISAI Inc and Arena Pharmaceuticals announce FDA approval of Belviq XR (lorcaserin HCL) extended-release tablets .In connection with approval, arena will receive a $10 million milestone payment.  Full Article

Eisai, Arena announce regulatory approval of VENESPRI in Mexico
Thursday, 14 Jul 2016 

Arena Pharmaceuticals Inc : Eisai and Arena Pharmaceuticals announce regulatory approval of VENESPRI® (lorcaserin HCl) in Mexico . In connection with the approval, Arena will receive a $1 million milestone payment . In connection with the approval, Arena will receive a $1 million milestone payment .VENESPRI® is expected to become available later this year.  Full Article

Arena Pharmaceuticals to emphasize on its proprietary clinical stage pipeline
Friday, 1 Jul 2016 

Arena Pharmaceuticals: Arena Pharmaceuticals Inc says strategic shifting of priorities to emphasize its proprietary clinical stage pipeline . Arena Pharmaceuticals Inc says implementation of additional cost reductions to streamline organization to support its development programs . Arena pharmaceuticals inc says will reduce its us workforce by approximately 100 employees, or 73%, primarily in areas of research, manufacturing and G&A . Estimates cost reductions to result in reduced cash expenditures for personnel by about $17 million . Plans to implement additional cost control measures to further reduce expenditures, including reductions at Swiss manufacturing facility .As a result of us workforce reduction, estimates it will incur restructuring charges, primarily in q2 of 2016, of about $6.1 million.  Full Article

Arena Pharmaceuticals files for mixed shelf of up to $250 mln
Wednesday, 15 Jun 2016 

Arena Pharmaceuticals Inc :Arena Pharmaceuticals Inc files for mixed shelf of up to $250 million - SEC filing.  Full Article

Arena Pharmaceuticals Q1 loss per share $0.09
Tuesday, 10 May 2016 

Arena Pharmaceuticals Inc : Amit munshi appointed chief executive officer . Arena pharmaceuticals reports first quarter 2016 financial results and provides corporate update . Q1 loss per share $0.09 . Q1 revenue $9.8 million versus i/b/e/s view $9 million .Q1 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

Boehringer Ingelheim and Arena Pharmaceuticals collaborate to advance research in Schizophrenia
Wednesday, 13 Jan 2016 

Arena Pharmaceuticals Inc:Says the company and Arena Pharmaceuticals, Inc have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), which belongs to the group of orphan CNS receptors.New partnership further supports Boehringer Ingelheim's CNS pipeline projects.  Full Article

BRIEF-Arena Pharmaceuticals reports Q3 loss per share $0.86

* Arena Pharmaceuticals provides corporate update and reports third quarter 2017 financial results